Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 14/20 | 0.64 |
| ▸ | CDK1 | P06493 | 7/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.46 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7203529 | 0.92 | CDK2 (0.73) | CDK2CDK1EGFRERBB3 | |
| SCHEMBL7639290 | 0.89 | CDK2 (0.62) | CDK2CDK1MEN1MAPTKMT2A | |
| SCHEMBL7208562 | 0.84 | CDK2 (0.72) | CDK2CDK1MEN1MAPTKMT2A | |
| SCHEMBL7545155 | 0.82 | CDK2 (0.60) | CDK2CDK1 | |
| SCHEMBL7210391 | 0.82 | CDK2 (0.62) | CDK2CDK1MEN1MAPTKMT2A | |
| SCHEMBL7537529 | 0.75 | MAOB (0.56) | CDK2CDK1MEN1MAPTKMT2A | |
| SCHEMBL7536409 | 0.71 | CDK2 (0.60) | CDK2CDK1MEN1MAPTKMT2A | |
| SCHEMBL21262456 | 0.69 | TNIK (0.63) | CDK2CDK1MAPTTNIK | |
| SCHEMBL7204485 | 0.69 | TNIK (0.60) | CDK2CDK1TNIK | |
| SCHEMBL21262797 | 0.67 | TNIK (0.61) | CDK2CDK1MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1274706-A1 | PYRAZOLES FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2003-01-15 | — | — | EP | disclosed |
| US-6462069-B2 | KINASE INHIBITORS; ANTICANCER AGENTS | AGOURON PHARMACEUTICALS, INC. | 2002-10-08 | — | — | US | disclosed |
| WO-2001079198-A9 | PYRAZOLES FOR INHIBITING PROTEIN KINASE | AGOURON PHARMA (US) | 2002-05-16 | — | — | WO | disclosed |
| US-20020006952-A1 | Compounds, pharmaceutical compositions, and methods for inhibiting protein kinases | LIGHPOINTE COMMUNICATION, INC. | 2002-01-17 | — | — | US | disclosed |
| WO-2001079198-A1 | PYRAZOLES FOR INHIBITING PROTEIN KINASE | AGOURON PHARMACEUTICALS, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006952-A1 | Compounds, pharmaceutical compositions, and methods for inhibiting protein kinases | CDK3, CCNK, CDK1 | CDK2 4/4885CDK1 3/4885MEN1 4356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.